Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing isosorbide mononitrate for treating high blood pressure

A technology of isosorbide dinitrate and composition, applied in the field of new pharmaceutical compositions, can solve problems such as increased pulse pressure, and achieve the effects of reducing arterial pressure, overcoming the increase in pulse pressure, and reducing blood pressure

Inactive Publication Date: 2005-07-06
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Nowadays, for the treatment of hypertension, a single drug often cannot achieve the desired effect. In clinical practice, two or more antihypertensive drugs are often used in combination to achieve better antihypertensive effect, but it still cannot overcome the arterial A phenomenon in which the pulse pressure increases while the blood pressure decreases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Isosorbide Mononitrate Nitrendipine Extended Release Tablets

[0019] Prescription A

[0020] Isosorbide Mononitrate 15g

[0021] Starch 50g

[0022] L--HPC 20g

[0023] 10% starch slurry appropriate amount

[0024] Magnesium Stearate 1g

[0025] Prescription B

[0026] Nitrendipine 15g

[0027] HPMC--4M 20g

[0028] HPMC--15M 30g

[0029] Microcrystalline Cellulose 20g

[0030] PVP 8g

[0031] Micronized silica gel 35g

[0032]8% PVPk30 absolute ethanol solution appropriate amount

[0033] Magnesium Stearate 2g

[0034] Preparation Process:

[0035] Pass the isosorbide mononitrate, starch, and L-HPC in prescription A through a 100-mesh sieve, mix well, add 10% starch slurry to granulate, dry below 50°C, granulate with a 18-mesh sieve, and add stearic acid Magnesium mix well; pass nitrendipine, HPMC--4M, HPMC--15M,...

Embodiment 2

[0037] Isosorbide Mononitrate Captopril Tablets

[0038] Isosorbide Mononitrate 10g

[0039] Captopril 50g

[0040] Starch 60g

[0041] Microcrystalline Cellulose 100g

[0042] L-HPC 30g

[0043] 10% starch slurry appropriate amount

[0044] Magnesium Stearate 2g

[0045] Preparation Process:

[0046] Pass the isosorbide mononitrate, captopril, starch, microcrystalline cellulose and L-HPC in the prescription through a 100-mesh sieve respectively, mix well, add 10% starch slurry to granulate in an appropriate amount, dry below 50°C, and dry for 18 Mesh sieve for granulation, add prescription amount of magnesium stearate, mix evenly, and compress into tablets.

Embodiment 3

[0048] Isosorbide Mononitrate Nifedipine Extended Release Tablets

[0049] Prescription A

[0050] Isosorbide Mononitrate 20g

[0051] Starch 100g

[0052] Sodium carboxymethyl starch 10g

[0053] 10% starch slurry appropriate amount

[0054] Magnesium Stearate 1g

[0055] Prescription B

[0056] Nifedipine 15g

[0057] Cetyl Alcohol 10g

[0058] Glyceryl monostearate 20g

[0059] Microcrystalline Cellulose 40g

[0060] 8% PVPk30 absolute ethanol solution appropriate amount

[0061] Magnesium Stearate 2g

[0062] Preparation Process:

[0063] Pass the isosorbide mononitrate, starch, and sodium carboxymethyl starch in prescription A through a 100-mesh sieve, mix well, add 10% starch slurry to granulate, dry below 50°C, granulate with a 18-mesh sieve, add hard Magnesium stearate and mix well; pass the nifedipine, cetyl alcohol, glyceryl ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The expansion of pulse pressure (PP) is the individual dangerous cardiovascular (CV) factor, by integrating Isosorbide Mononitrate with other hypertension resisting medicaments, good clinic curative effect is obtained, and synergy effect is achieved in terms of reduction of contraction pressure, wherein the combination of calcium ion antagonist, rennin-angiotensins-aldosterone system antagon, blood vessel expanding agent, epinephrine acceptor retarding agent can make the most ideal effect. The invention realizes the functions of reducing contraction pressure, mitigating unwanted reaction caused by hypertension medicament, and effectively increasing survival rate of hypertension patients.

Description

technical field [0001] The invention belongs to the medical technology and relates to a new pharmaceutical composition for the treatment of elderly hypertension. Background technique [0002] New developments in the theory of drug therapy for hypertension [0003] In the treatment of hypertensive patients, paying attention to whether the long-term survival rate of patients has been significantly improved is a great progress in the theory of hypertension treatment in recent years. Previously, it was thought that diastolic blood pressure (DBP) was a better indicator to determine the severity of hypertension, and the goal of drug treatment was to reduce DBP to less than 90, 85 or 80mmHg. Systolic blood pressure (SBP) is also reduced, but the degree of reduction is less than DBP, so PP cannot be reduced to normal. The results showed that although drug treatment normalized DBP, there was no further improvement in cardiovascular (CV) risk. Epidemiological studies in recent deca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/34A61K31/401A61K45/06A61P9/12
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com